Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
October 26, 2017 07:00 ET
|
Idera Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and EXTON, Pa. , Oct. 26, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) (“Idera” or the “Company”) today announced the pricing of its underwritten public...
Idera Pharmaceuticals Provides Corporate Governance Update
October 24, 2017 16:01 ET
|
Idera Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and EXTON, Pa., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
Idera Pharmaceuticals Announces Proposed Public Offering of Common Stock
October 24, 2017 16:01 ET
|
Idera Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and EXTON, Pa, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) (“Idera” or the “Company”) today announced that it intends to offer and sell up to $60...
Idera Pharmaceuticals Presents Pre-Clinical Data from IMO-2125 Treatment in Combination with Ipilimumab that Demonstrates Induction of Durable Anti-tumor Responses Associated with Tumor-Specific Memory
September 08, 2017 07:30 ET
|
Idera Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and EXTON, Pa., Sept. 08, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
Idera to Host Investor Conference Call on Monday, September 11, 2017 at 9:00 A.M. E.T.
September 06, 2017 13:00 ET
|
Idera Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and EXTON, Pa., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
Idera to Present at the 2017 Wedbush PacGrow Healthcare Conference
August 11, 2017 11:00 ET
|
Idera Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and EXTON, Pa., Aug. 11, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
Idera Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
August 07, 2017 17:00 ET
|
Idera Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and EXTON, Pa., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Idera Announces FDA Orphan Drug Designation for IMO-2125 for the Treatment of Melanoma
June 22, 2017 16:30 ET
|
Idera Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and EXTON, Pa., June 22, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
Idera to Present at the Jefferies 2017 Healthcare Conference
June 05, 2017 11:00 ET
|
Idera Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and EXTON, Pa., June 05, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
Idera Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
May 04, 2017 16:01 ET
|
Idera Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and EXTON, Pa., May 04, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and...